Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Rigel Pharmaceuticals News

Aktie
WKN:  A40EFY ISIN:  US7665597024 US-Symbol:  RIGL Branche:  Biotechnologie Land:  USA
32,51 $
+0,71 $
+2,23%
27,635 € 17.04.26
Depot/Watchlist
Marktkapitalisierung *
668,09 Mio. €
Streubesitz
13,22%
KGV
17,34
Index-Zuordnung
-

Rigel Pharmaceuticals News

07.04.26 - PR Newswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire
31.03.26 - PR Newswire
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology PR Newswire
24.02.26 - PR Newswire
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update PR Newswire
03.02.26 - PR Newswire
Rigel Appoints Michael P. Miller to the Board of Directors
Rigel Appoints Michael P. Miller to the Board of Directors PR Newswire
12.01.26 - PR Newswire
Rigel Provides Business Update and 2026 Outlook
Rigel Provides Business Update and 2026 Outlook PR Newswire
09.01.26 - PR Newswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire
07.01.26 - PR Newswire
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
07.12.25 - PR Newswire
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-​Risk MDS at the 67th ASH Annual Meeting and Exposition PR Newswire
26.11.25 - PR Newswire
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference PR Newswire
17.11.25 - PR Newswire
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology PR Newswire
12.11.25 - PR Newswire
Rigel to Present at the Jefferies Global Healthcare Conference in London
Rigel to Present at the Jefferies Global Healthcare Conference in London PR Newswire
04.11.25 - PR Newswire
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire
03.11.25 - PR Newswire
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition PR Newswire
29.10.25 - PR Newswire
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update PR Newswire
08.10.25 - PR Newswire
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-​Risk MDS PR Newswire
03.10.25 - PR Newswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire
26.08.25 - PR Newswire
Rigel to Participate in Upcoming September Investor Conferences
Rigel to Participate in Upcoming September Investor Conferences PR Newswire
05.08.25 - PR Newswire
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire
29.07.25 - PR Newswire
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update PR Newswire
07.07.25 - PR Newswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »